BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11313694)

  • 1. Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature.
    Mileshkin L; Prince HM; Rischin D; Zimet A
    Bone Marrow Transplant; 2001 Mar; 27(5):559-63. PubMed ID: 11313694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
    Prince HM; Rischin D; Toner GC; Seymour JF; Blakey D; Gates P; Eerhard S; Chapple P; Quinn M; Brettell M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P
    Bone Marrow Transplant; 2000 Nov; 26(9):955-61. PubMed ID: 11100274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
    Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interstitial pneumonitis as a late complication of high dose therapy with cyclophosphamide/thiotepa and peripheral blood progenitor cell rescue for carcinoma of the breast.
    Mahendra P; Hood IM; Lee MA; Mewar D; Bass G; Flower CD; Wilson CB; Marcus RE
    Clin Oncol (R Coll Radiol); 1996; 8(3):198-200. PubMed ID: 8814378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palliative chemotherapy after failure of high-dose chemotherapy in breast cancer--toxicity and efficacy.
    Schrama JG; de Boer MM; Baars JW; Schornagel JH; Rodenhuis S
    Anticancer Res; 2003; 23(3C):2795-800. PubMed ID: 12926115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study.
    Zander AR; Krüger W; Kröger N; Damon L; Königmann M; Berdel WE; Gieseking F; Schäfer-Eckart K; Möbus V; Frickhofen N; Wandt H; Illiger HJ; Metzner B; Kolbe K; Wörmann B; Trümper L; Huber C; Hossfeld DK; Maass H; Jonat W
    Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S24-5. PubMed ID: 8899165
    [No Abstract]   [Full Text] [Related]  

  • 7. Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
    Morabito F; Irrera G; Oliva E; Console G; Martino M; Pucci G; Messina G; Barbaro P; Palazzo S; Iacopino P
    Bone Marrow Transplant; 2001 Nov; 28(9):883-8. PubMed ID: 11781650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
    Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
    Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy (CTM) for breast cancer.
    Damon LE; Wolf JL; Rugo HS; Gold E; Zander AR; Cassidy M; Cecchi G; Cohen N; Irwin D; Tracy M; Ries CA; Linker CA
    Bone Marrow Transplant; 2000 Aug; 26(3):257-68. PubMed ID: 10967563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.
    Stadtmauer EA; O'Neill A; Goldstein LJ; Crilley PA; Mangan KF; Ingle JN; Brodsky I; Martino S; Lazarus HM; Erban JK; Sickles C; Glick JH
    N Engl J Med; 2000 Apr; 342(15):1069-76. PubMed ID: 10760307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
    Kröger N; Frick M; Gluz O; Mohrmann S; Metzner B; Jackisch C; Ko Y; Lindemann HW; Meier CR; Lohrmann HP; Ruffert U; Hänel M; Bodenstein H; Neubauer A; Ehninger G; Wolf HH; Kolbe K; Burock K; Zander AR; Nitz U
    J Clin Oncol; 2006 Aug; 24(24):3919-26. PubMed ID: 16921043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer.
    Wong R; Rondon G; Saliba RM; Shannon VR; Giralt SA; Champlin RE; Ueno NT
    Bone Marrow Transplant; 2003 Jun; 31(12):1157-63. PubMed ID: 12796796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients.
    Kim S; Tannock I; Sridhar S; Seki J; Bordeleau L
    J Oncol Pharm Pract; 2012 Jun; 18(2):311-5. PubMed ID: 22217649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
    Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
    Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
    deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E
    Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.
    Tiersten A; Wo J; Jacobson C; Weitzman A; Horwich T; Hesdorffer C; Savage D; Troxel A
    Breast; 2004 Aug; 13(4):341-6. PubMed ID: 15325671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer.
    Tomás JF; Pérez-Carrión R; Escudero A; López-Lorenzo JL; López-Pascual J; Fernández-Rañada JM
    Bone Marrow Transplant; 1997 Feb; 19(4):331-6. PubMed ID: 9051242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
    Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
    Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.